MG
XGN icon

Michael Gelband’s Exagen XGN Stock Holding History

Michael Gelband’s Portfolio XGN Stock Details XGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-39,321
Closed -$239K – 2162
2025
Q4 		$239K Buy
39,321
+29,037
+282% +$264K ﹤0.01% 1360
2025
Q3 		$113K Buy
+10,284
New +$91.1K ﹤0.01% 1421

Other funds holding XGN

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
SAM
Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
FCM
FourWorld Capital Management New York $110M AUM 44.07% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
MBAM
Mink Brook Asset Management West Palm Beach, Florida $227M AUM 64.76% 1-Year Est. Return

Michael Gelband's XGN Position: Q1 2026 in Review

Michael Gelband sold out of Exagen (XGN) in Q1 2026, closing a stake of 39,321 shares — an estimated $239K sold.

Michael Gelband first reported a position in XGN in Q3 2025 and held it in 2 quarters. The position peaked at $239K in Q4 2025. 61 funds tracked by Wall St. Rank hold XGN as of Q1 2026.

  • Michael Gelband reported no remaining Exagen position as of Q1 2026 after selling out during the quarter.
  • Michael Gelband sold 39,321 Exagen shares in Q1 2026, an estimated $239K.
  • Michael Gelband first reported a position in Exagen in Q3 2025 and held it in 2 quarters.
  • Michael Gelband's Exagen position peaked at $239K in Q4 2025.
  • 61 funds tracked by Wall St. Rank held Exagen as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.